{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"tyrosinemia-type-ii","columns":[{"gene":"","key":"population-0aa8657b3e746c3734d0","label":"Tyrosine transaminase deficiency","mondoId":"MONDO:0010160","onsetQualifier":null,"originColumnKey":"MONDO:0010160/OMIM:276600","originalViews":[{"key":"MONDO:0010160/OMIM:276600","label":"Tyrosine transaminase deficiency","scopeLabel":"OMIM:276600","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["06b4275566c213663f13f06f67320383c046c83f1408ce2bc90a30201c637c8e","16e34f7b52fa1c96050a516250a494e809f71f3de74561c00089804b7ce43e3d","2692985b2cbc8be0daa29323024a8306832e31d22bd5d257642a2df19eeb9518","a3eabd553383c1398928771763a1f419a5969d400baf136d7567ced07c528e95","c2afeecbb9f772c3c4df8e0a08e5912ec1b9877ca233dad12fa3e2873f0787cd","da1a73dad2da4a05028bbd9544fa094bd799567a519693ea0eca707e0bdd2ae1","e8ff754b71a77e425f19c89b4b1d94d41b4e3c58f1201877006a7c74c118cde0"],"recordQualifiers":{},"scopeLabel":"OMIM:276600","sourceIds":["OMIM:276600"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."},{"gene":"","key":"population-8a9c62bd1aafd12d96cd","label":"Tyrosinemia type 2","mondoId":"MONDO:0010160","onsetQualifier":null,"originColumnKey":"MONDO:0010160/ORPHA:28378","originalViews":[{"key":"MONDO:0010160/ORPHA:28378","label":"Tyrosinemia type 2","scopeLabel":"ORPHA:28378","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["0b3f14bad64e08f3250bd517cef79d3a0e6f07e6897e6b849d39dd2b575adb5b","11dadb41e641b61fb23f671428fd5725d5b734f7f744114a7c832f1f79be3616","1e9873093c532a1dfa250ca618c5c4e7e6a448f708331cc31fbfb5cfe26a1844","1f03a5f5508d0bce26c9bbc7a114e269786da3c0998f0b09aa7414f63f960edb","242602406661dba5f32346eea2b09fa25711fe720a1faa70eee5238e22b4feb6","43a1a9e8f8b568b462ad6e026880fefab1cfe8ab889358ed562e538810b8e379","4fe1aca815a71e52288eebd15a0b20bdaa9ee15a09ca456d25a996306db2ac07","56ca41512a69295c251ffc3b3e9fef543f56d4b7a040e970a05c7a14385d7c61","5aaa762939d635a18aa562b5c1c8f624d311a2577e870aeaa4afccf215507b93","5e5e75070960debaa43e8e8d30b5b263111042305d603abe3edfe705da322818","5ee2c5dd41a9ba62a940267199026915c593007547a4df40731ae5e336073134","671a00af8bd918c69ed2e473d73c744b6b4d9df168fd6619c5b2526e88deca4b","89b37157d8de907237bf379d7572967a157a8da8752589b1fbd8fcd08f09e43a","b19fdf24763b3ad15e2323d755962bccad0bce46037766a3be530d239ac14ed4","bb0d6f544640b7846a3f38a7d15ee4a264919e7ccc092c6515f81fc502febbb7","e0313e20db6865e440b4dd5b4f48bf738fabe76c39dc53fbd9181604080bcb95","fdc75971320c55beaa20b715cf0ee427b7a88ecb6bfc8013eda58acc981115c1"],"recordQualifiers":{},"scopeLabel":"ORPHA:28378","sourceIds":["ORPHA:28378"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-0aa8657b3e746c3734d0","population-8a9c62bd1aafd12d96cd"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0003161","HP:0001597","HP:0002167","HP:0004337","HP:0000951","HP:0001251","HP:0000708"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":24,"sourceGroups":{"omim":6,"orphanet":17,"published":1}},"features":[{"hpoId":"HP:0003161","label":"4-Hydroxyphenylpyruvic aciduria","primary":true},{"hpoId":"HP:0001597","label":"Abnormal nail morphology","primary":true},{"hpoId":"HP:0002167","label":"Abnormal speech pattern","primary":true},{"hpoId":"HP:0004337","label":"Abnormality of amino acid metabolism","primary":true},{"hpoId":"HP:0000951","label":"Abnormality of the skin","primary":true},{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0000708","label":"Atypical behavior","primary":true},{"hpoId":"HP:0007957","label":"Corneal opacity","primary":false},{"hpoId":"HP:6000479","label":"Elevated urine N-acetyltyrosine level","primary":false},{"hpoId":"HP:0001510","label":"Growth delay","primary":false},{"hpoId":"HP:0007812","label":"Herpetiform corneal ulceration","primary":false},{"hpoId":"HP:0000975","label":"Hyperhidrosis","primary":false},{"hpoId":"HP:0000962","label":"Hyperkeratosis","primary":false},{"hpoId":"HP:0003231","label":"Hypertyrosinemia","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0000272","label":"Malar flattening","primary":false},{"hpoId":"HP:0000252","label":"Microcephaly","primary":false},{"hpoId":"HP:0000639","label":"Nystagmus","primary":false},{"hpoId":"HP:0000982","label":"Palmoplantar keratoderma","primary":false},{"hpoId":"HP:0000613","label":"Photophobia","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0001337","label":"Tremor","primary":false},{"hpoId":"HP:0000572","label":"Visual loss","primary":false}],"ledeHtml":"Tyrosinemia type II is characterized by corneal dystrophy, painful palmoplantar hyperkeratosis, and variable intellectual disability. Individuals diagnosed and treated from early infancy may be asymptomatic or have only mild ocular and skin manifestations. Individuals with delayed diagnosis or lack of treatment present with ocular, skin, and variable cognitive manifestations.","mondoId":"MONDO:0010160","node":{"canonicalSlug":"tyrosinemia-type-ii","comparisons":[{"documentSha256":"9e8185d674eaef65f59d3441ebee524b95f0674d9b6014b4433e55168452d58a","key":"legacy-tyrosinemia","kind":"legacy","label":"tyrosinemia","memberIds":["MONDO:0004741","MONDO:0010160","MONDO:0010161","MONDO:0010162"],"mondoId":"MONDO:0004741","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/tyrosinemia.9e8185d674eaef65f59d3441ebee524b95f0674d9b6014b4433e55168452d58a.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","matchMethod":"automatic-preferred-title","name":"Tyrosinemia Type II","paragraphs":["Tyrosinemia type II is characterized by corneal dystrophy, painful palmoplantar hyperkeratosis, and variable intellectual disability. Individuals diagnosed and treated from early infancy may be asymptomatic or have only mild ocular and skin manifestations. Individuals with delayed diagnosis or lack of treatment present with ocular, skin, and variable cognitive manifestations."],"reviewed":"2024-10-24","scope":"exact","source":"GeneReviews","sourceExcerpt":"Summary / Clinical characteristics","sourceRelease":"2026-10-18 12:12:25.246447+00","upstream":"GeneReviews clinical characteristics","url":"https://www.ncbi.nlm.nih.gov/books/NBK608431/"},"ownColumnKeys":["population-0aa8657b3e746c3734d0","population-8a9c62bd1aafd12d96cd"],"publication":"published","relationships":[{"kind":"parent","label":"tyrosinemia","mondoId":"MONDO:0004741","slug":"tyrosinemia"},{"kind":"parent","label":"eye disorder","mondoId":"MONDO:0005328","slug":null},{"kind":"parent","label":"focal palmoplantar keratoderma","mondoId":"MONDO:0017672","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/3105","pageMondoId":"MONDO:0010160","source":"GARD","name":"Tyrosinemia type II","url":"https://rarediseases.info.nih.gov/diseases/3105","relationToPage":"same-condition","coveredMondoIds":["MONDO:0010160"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-25T03:38:56Z","upstream":"GARD:0003105","rawAttribution":"MONDO:0010160","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"reported","key":"06b4275566c213663f13f06f67320383c046c83f1408ce2bc90a30201c637c8e","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003231","is_excluded":false,"label":"Hypertyrosinemia","onset_id":null,"reference":"OMIM:276600","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"0b3f14bad64e08f3250bd517cef79d3a0e6f07e6897e6b849d39dd2b575adb5b","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"11dadb41e641b61fb23f671428fd5725d5b734f7f744114a7c832f1f79be3616","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000962","is_excluded":false,"label":"Hyperkeratosis","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"16e34f7b52fa1c96050a516250a494e809f71f3de74561c00089804b7ce43e3d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:6000479","is_excluded":false,"label":"Elevated urine N-acetyltyrosine level","onset_id":null,"reference":"PMID:20301688","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"1e9873093c532a1dfa250ca618c5c4e7e6a448f708331cc31fbfb5cfe26a1844","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000708","is_excluded":false,"label":"Atypical behavior","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"1f03a5f5508d0bce26c9bbc7a114e269786da3c0998f0b09aa7414f63f960edb","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"242602406661dba5f32346eea2b09fa25711fe720a1faa70eee5238e22b4feb6","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000613","is_excluded":false,"label":"Photophobia","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"2692985b2cbc8be0daa29323024a8306832e31d22bd5d257642a2df19eeb9518","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"OMIM:276600","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"43a1a9e8f8b568b462ad6e026880fefab1cfe8ab889358ed562e538810b8e379","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000252","is_excluded":false,"label":"Microcephaly","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4fe1aca815a71e52288eebd15a0b20bdaa9ee15a09ca456d25a996306db2ac07","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001597","is_excluded":false,"label":"Abnormal nail morphology","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"56ca41512a69295c251ffc3b3e9fef543f56d4b7a040e970a05c7a14385d7c61","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0007957","is_excluded":false,"label":"Corneal opacity","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5aaa762939d635a18aa562b5c1c8f624d311a2577e870aeaa4afccf215507b93","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000272","is_excluded":false,"label":"Malar flattening","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5e5e75070960debaa43e8e8d30b5b263111042305d603abe3edfe705da322818","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001337","is_excluded":false,"label":"Tremor","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5ee2c5dd41a9ba62a940267199026915c593007547a4df40731ae5e336073134","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000975","is_excluded":false,"label":"Hyperhidrosis","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"671a00af8bd918c69ed2e473d73c744b6b4d9df168fd6619c5b2526e88deca4b","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002167","is_excluded":false,"label":"Abnormal speech pattern","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"89b37157d8de907237bf379d7572967a157a8da8752589b1fbd8fcd08f09e43a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0004337","is_excluded":false,"label":"Abnormality of amino acid metabolism","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"a3eabd553383c1398928771763a1f419a5969d400baf136d7567ced07c528e95","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0007812","is_excluded":false,"label":"Herpetiform corneal ulceration","onset_id":null,"reference":"OMIM:276600","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"b19fdf24763b3ad15e2323d755962bccad0bce46037766a3be530d239ac14ed4","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bb0d6f544640b7846a3f38a7d15ee4a264919e7ccc092c6515f81fc502febbb7","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000572","is_excluded":false,"label":"Visual loss","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"c2afeecbb9f772c3c4df8e0a08e5912ec1b9877ca233dad12fa3e2873f0787cd","raw":{"aspect":"P","body_system":"growth","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001510","is_excluded":false,"label":"Growth delay","onset_id":null,"reference":"OMIM:276600","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"da1a73dad2da4a05028bbd9544fa094bd799567a519693ea0eca707e0bdd2ae1","raw":{"aspect":"P","body_system":"skin","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000951","is_excluded":false,"label":"Abnormality of the skin","onset_id":null,"reference":"OMIM:276600","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"e0313e20db6865e440b4dd5b4f48bf738fabe76c39dc53fbd9181604080bcb95","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000982","is_excluded":false,"label":"Palmoplantar keratoderma","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"e8ff754b71a77e425f19c89b4b1d94d41b4e3c58f1201877006a7c74c118cde0","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:276600","disease_name":"Tyrosine transaminase deficiency","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003161","is_excluded":false,"label":"4-Hydroxyphenylpyruvic aciduria","onset_id":null,"reference":"OMIM:276600","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"fdc75971320c55beaa20b715cf0ee427b7a88ecb6bfc8013eda58acc981115c1","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:28378","disease_name":"Tyrosinemia type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000639","is_excluded":false,"label":"Nystagmus","onset_id":null,"reference":"ORPHA:28378","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK608431/\" rel=\"noreferrer\">GeneReviews</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/3105\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0010160\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-preferred-title</dd><dt>Upstream attribution</dt><dd>GeneReviews clinical characteristics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Tyrosinemia type II is characterized by corneal dystrophy, painful palmoplantar hyperkeratosis, and variable intellectual disability. Individuals diagnosed and treated from early infancy may be asymptomatic or have only mild ocular and skin manifestations. Individuals with delayed diagnosis or lack of treatment present with ocular, skin, and variable cognitive manifestations.</p><p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK608431/\" rel=\"noreferrer\">GeneReviews</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"tyrosinemia-type-ii","sourceDocuments":[{"name":"GeneReviews: Tyrosinemia Type II","reviewed":"2024-10-24","source_release":"2026-10-18 12:12:25.246447+00","url":"https://www.ncbi.nlm.nih.gov/books/NBK608431/"},{"name":"GARD: Tyrosinemia type II","reviewed":null,"source_release":"2026-10-25T03:38:56Z","url":"https://rarediseases.info.nih.gov/diseases/3105"},{"name":"MONDO: tyrosinemia type II","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0010160"}],"sourceNote":"","synonyms":["keratosis palmoplantaris-corneal dystrophy syndrome","oculocutaneous tyrosinemia","Richner Hanhart syndrome","Richner-Hanhart syndrome","tyrosinemia due to TAT deficiency","tyrosinemia due to tyrosine aminotransferase deficiency","tyrosinemia type 2","tyrosinemia type II","tyrosinemia, type II","Tyrosinosis oculocutaneous type","TYRSN2"],"takeawayHtml":"","title":"tyrosinemia type II"},"schemaVersion":1}
